Search research articles
Contact Us
Filters
Showing results (191-200 of 327) with videos related to
Page
of 33
Sort By:
Biorxiv : the Preprint Server for Biology
|
September 24, 2024
A Comprehensive Proteogenomic and Spatial Analysis of Innate and Acquired Resistance of Metastatic Melanoma to Immune Checkpoint Blockade Therapies
Shiyou Wei, Kuang Du, Hongbin Lan, et al.
Kidney International Reports
|
October 26, 2020
Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors
Harish Seethapathy, Sophia Zhao, Ian A Strohbehn, et al.
Cancer
|
April 12, 2023
Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors
Meghan J Mooradian, James M Cleary, Anita Giobbie-Hurder, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 18, 2021
Immune checkpoint inhibitors for cancer and venous thromboembolic events
Jingyi Gong, Zsofia D Drobni, Raza M Alvi, et al.
JAAD International
|
November 25, 2022
The impact of stage-related features in melanoma recurrence prediction: A machine learning approach
Guihong Wan, Bonnie Leung, Nga Nguyen, et al.
Cancer
|
August 18, 2016
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies
Alain P Algazi, Katy K Tsai, Alexander N Shoushtari, et al.
The Oncologist
|
May 1, 2021
Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center
Leyre Zubiri, Rachel P Rosovsky, Meghan J Mooradian, et al.
JAMA Dermatology
|
March 12, 2025
Characterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint Inhibitors
Kylie A Fletcher, Rachel S Goodman, Aleigha Lawless, et al.
The Oncologist
|
November 19, 2024
Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma
Jeffrey Weber, Waqas Haque, Svetomir N Markovic, et al.
Journal for Immunotherapy of Cancer
|
September 11, 2025
Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes
Lilach Aizenbud, Noam Savion Gaiger, Ana Luisa Perdigoto, et al.
Page
of 33
Search research articles
Search
Showing results (191-200 of 327) with videos related to
Sort By:
Page
of 33
Biorxiv : the Preprint Server for Biology
|
September 24, 2024
A Comprehensive Proteogenomic and Spatial Analysis of Innate and Acquired Resistance of Metastatic Melanoma to Immune Checkpoint Blockade Therapies
Shiyou Wei, Kuang Du, Hongbin Lan, et al.
Kidney International Reports
|
October 26, 2020
Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors
Harish Seethapathy, Sophia Zhao, Ian A Strohbehn, et al.
Cancer
|
April 12, 2023
Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors
Meghan J Mooradian, James M Cleary, Anita Giobbie-Hurder, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 18, 2021
Immune checkpoint inhibitors for cancer and venous thromboembolic events
Jingyi Gong, Zsofia D Drobni, Raza M Alvi, et al.
JAAD International
|
November 25, 2022
The impact of stage-related features in melanoma recurrence prediction: A machine learning approach
Guihong Wan, Bonnie Leung, Nga Nguyen, et al.
Cancer
|
August 18, 2016
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies
Alain P Algazi, Katy K Tsai, Alexander N Shoushtari, et al.
The Oncologist
|
May 1, 2021
Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center
Leyre Zubiri, Rachel P Rosovsky, Meghan J Mooradian, et al.
JAMA Dermatology
|
March 12, 2025
Characterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint Inhibitors
Kylie A Fletcher, Rachel S Goodman, Aleigha Lawless, et al.
The Oncologist
|
November 19, 2024
Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma
Jeffrey Weber, Waqas Haque, Svetomir N Markovic, et al.
Journal for Immunotherapy of Cancer
|
September 11, 2025
Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes
Lilach Aizenbud, Noam Savion Gaiger, Ana Luisa Perdigoto, et al.
Page
of 33